William Nichols
Technik-/Wissenschafts-/F&E-Leiter bei CANDEL THERAPEUTICS, INC.
Vermögen: 120 308 $ am 30.04.2024
Profil
William Garrett Nichols is currently the Chief Medical Officer at Candel Therapeutics, Inc. Prior to this, he was the Chief Medical Officer at Chimerix, Inc. from 2014 to 2020.
He also served as the Chief Medical Officer at Istari Oncology, Inc. from 2020 to 2022.
Before his career in the pharmaceutical industry, he received a doctorate degree from Duke University and a graduate degree from the University of Washington.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2024 | 17 065 ( 0,06% ) | 120 308 $ | 30.04.2024 |
Aktive Positionen von William Nichols
| Unternehmen | Position | Beginn |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.09.2022 |
Ehemalige bekannte Positionen von William Nichols
| Unternehmen | Position | Ende |
|---|---|---|
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2022 |
| CHIMERIX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 07.04.2020 |
ViiV Healthcare Ltd.
 ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von William Nichols
| Duke University | Doctorate Degree |
| University of Washington | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
